Results 251 to 260 of about 90,382 (271)
Some of the next articles are maybe not open access.
AIDS, 2000
Objective To determine the influence of CCR5 promoter polymorphisms on HIV-1 progression to AIDS and to evaluate the interaction between CCR5 structural polymorphisms and those occurring in the regulatory region of the same gene. Participants Seventy-one HIV-1-infected long-term non-progressors with a CD4+ T cell count of > 500 x 10(6)/I more than 8
Alison O. Clegg +6 more
openaire +1 more source
Objective To determine the influence of CCR5 promoter polymorphisms on HIV-1 progression to AIDS and to evaluate the interaction between CCR5 structural polymorphisms and those occurring in the regulatory region of the same gene. Participants Seventy-one HIV-1-infected long-term non-progressors with a CD4+ T cell count of > 500 x 10(6)/I more than 8
Alison O. Clegg +6 more
openaire +1 more source
Recent advances of CCR5 antagonists
Current Opinion in HIV and AIDS, 2006The interaction of the beta-chemokine receptor CCR5 with the HIV-1 envelope glycoprotein gp120 is critical for viral entry. Therefore, CCR5 seems to be a promising target for inhibition of HIV-1 replication. A number of attempts have been made to identify small-molecule CCR5 antagonists as novel antiretroviral agents.
openaire +2 more sources
2021
Five Ukrainian populations have been genotyped for a deletion polymorphism del32 in CCR5 gene. It has been shown that frequency of this allele in Ukrainians is similar to that of the other Slavic populations.
openaire +1 more source
Five Ukrainian populations have been genotyped for a deletion polymorphism del32 in CCR5 gene. It has been shown that frequency of this allele in Ukrainians is similar to that of the other Slavic populations.
openaire +1 more source
CCR5 inhibitors: emergence, success, and challenges
Expert Opinion on Emerging Drugs, 2012The discovery of CC-chemokine receptor 5 (CCR5) as a human immunodeficiency virus type 1 (HIV-1) coreceptor opened a new avenue to exploit CCR5 as a potential target for the intervention of HIV-1's cellular entry.Various small-molecule CCR5 inhibitors were identified in the last decade; however, maraviroc (MVC) is the only CCR5 inhibitor currently used
Kenji, Maeda +3 more
openaire +2 more sources
Future HIV Therapy, 2008
HIV requires binding to both the CD4 molecule and a coreceptor to enable entry into the cell. CCR5 is a chemokine receptor that is utilized as a coreceptor by the majority of virus in early asymptomatic HIV infection. Maraviroc is a novel small molecule CCR5 antagonist which, in Phase IIb/III clinical trials up to 48 weeks, has been shown to be ...
LKK Tan, M Nelson
openaire +1 more source
HIV requires binding to both the CD4 molecule and a coreceptor to enable entry into the cell. CCR5 is a chemokine receptor that is utilized as a coreceptor by the majority of virus in early asymptomatic HIV infection. Maraviroc is a novel small molecule CCR5 antagonist which, in Phase IIb/III clinical trials up to 48 weeks, has been shown to be ...
LKK Tan, M Nelson
openaire +1 more source
CCR5 antagonists: เป้าหมายใหม่ในการรักษาโรคเอดส์
1( Jan-Dec), 2550, ไทยไภษัชยนิพนธ์openaire +1 more source
Langzeitverträglichkeit von CCR5-Inhibitoren
2008In den vergangenen Jahren sind erhebliche Fortschritte bei der Behandlung der HIV-1-Infektion erzielt worden. Leider mussten aber auch starke Nebenwirkungen und Langzeittoxizitaten beobachtet werden, die bei vielen Patienten zum Wechsel oder gar zum Abbruch der Therapie fuhrten.
openaire +1 more source